Sarepta prepares to present new data on Duchenne and limb-girdle muscular dystrophy gene therapy programs this week.

A New York panel has voted unanimously to recommend the state Medicaid program should pause coverage of a treatment for Duchenne muscular ...

In a setback for Sarepta Therapeutics, a New York panel has voted unanimously to recommend the state Medicaid program pause ...

Shares of Sarepta Therapeutics rose nearly 5% in early premarket trading on Wednesday as the company prepared to present new ...

A custom-built racetrack is allowing a 9-year-old with Duchenne Muscular Dystrophy to enjoy recess at Linda Vista Elementary using his wheelchair.

Key influencers of the FDA's decision to approve Sarepta's Duchenne muscular dystrophy drug, which was the subject of intense debate within the agency and scientific community ...

Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work ...

Innovative delivery vectors and more efficient processing can cut expenses and make CGT a cost-effective option.

The Neuromuscular Disease Therapeutics Market is entering a period of accelerated growth, supported by breakthroughs in gene ...

Long-term treatment with givinostat in boys with Duchenne muscular dystrophy continues to show a favourable safety and tolerability profile ...